Toedter GP, Brewer K, Hofheinz D; International Conference on AIDS.
Int Conf AIDS. 1996 Jul 7-12; 11: 81 (abstract no. Mo.B.1151).
Coulter Corporation, Miami, FL, USA. Fax: 305-380-3699.
Objective: To determine the specificity of confirmation testing of HIV-1 p24 positive samples in the pre-seroconversion window period. Methods: Twelve HIV-1 seroconversion panels, Panels A, C, E, G, I, J, L, P, R, V, Z, AD (Boston Biomedica, Boston, MA) were tested using the Coulter HIV-1 p24 Antigen Assay. Samples found to be initially reactive were repeat tested, then confirmed using the Coulter HIV-1 p24 Antigen Neutralization Kit. Results: Ninety-nine panel samples were screened. Of these, 51 antigen positive samples were identified, with an optical density range of 0.074 (S/C 1.10) to greater than 3.9 (S/C 50.8). When tested in the neutralization procedure, 50/51 of the samples met the criteria for neutralization (OD greater than cutoff, greater than 50% reduction of signal). One sample, with an estimated p24 concentration of greater than 1,250 pg/ml, needed to be diluted 1:10 prior to testing in order to met the 50% reduction criteria. Consequently, 51/51 initial reactive seroconversion panel samples could be confirmed with the neutralization procedure. Conclusion: It was confirmed that the neutralization procedure has the sensitivity to accurately confirm that a sample is HIV p24 antigen positive in samples obtained from individuals in the pre-seroconversion window period. Furthermore, the study has demonstrated that all window period samples found to be repeat reactive met the neutralization criteria. This study reflects data which will be found in a blood donor screening setting, as the seroconversion panel samples are collected from blood donor populations. Therefore, it can concluded that the data seen here is an accurate model for p24 antigen confirmation in blood donor screening.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Blood Donors
- Boston
- HIV Core Protein p24
- HIV Infections
- HIV Seropositivity
- Immunologic Techniques
- Mass Screening
- Research Design
- Sensitivity and Specificity
- immunology
- organization & administration
Other ID:
UI: 102217116
From Meeting Abstracts